$ANEB
Anebulo Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223041171 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.698M $1.273M $1.388M
YoY Change -12.63% -8.27% 65.3%
% of Gross Profit
Research & Development $1.063M $1.270M $1.224M
YoY Change -43.17% 3.8% 71.13%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.760M $2.544M $2.612M
YoY Change -27.61% -2.62% 67.99%
Operating Profit -$2.760M -$2.544M -$2.612M
YoY Change -27.61% -2.62% 67.99%
Interest Expense $31.84K $55.20K
YoY Change
% of Operating Profit
Other Income/Expense, Net $43.09K $62.86K $210.00
YoY Change -411.57% 29830.95% -86.27%
Pretax Income -$2.717M -$2.481M -$2.612M
YoY Change -28.99% -5.02% 68.14%
Income Tax
% Of Pretax Income
Net Earnings -$2.717M -$2.500M -$2.612M
YoY Change -28.99% -4.28% 68.14%
Net Earnings / Revenue
Basic Earnings Per Share -$0.11 -$0.10 -$0.11
Diluted Earnings Per Share -$0.11 -$0.10 -$111.5K
COMMON SHARES
Basic Shares Outstanding 25.63M shares 25.63M shares 23.37M shares
Diluted Shares Outstanding 25.79M shares 25.63M shares 23.42M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.645M $8.521M $19.21M
YoY Change -59.37% -55.65% 0.03%
Cash & Equivalents $6.645M $8.521M $19.21M
Short-Term Investments
Other Short-Term Assets $171.7K $527.3K $601.7K
YoY Change -67.77% -12.36% -53.45%
Inventory
Prepaid Expenses $171.7K $527.3K $601.7K
Receivables
Other Receivables
Total Short-Term Assets $6.816M $9.048M $19.82M
YoY Change -59.64% -54.34% -3.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K
YoY Change
Total Long-Term Assets $684.5K $4.00 -$5.00
YoY Change -17113000.0% -180.0%
TOTAL ASSETS
Total Short-Term Assets $6.816M $9.048M $19.82M
Total Long-Term Assets $684.5K $4.00 -$5.00
Total Assets $7.501M $9.048M $19.82M
YoY Change -55.59% -54.34% -3.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $318.7K $565.9K $523.5K
YoY Change -8.04% 8.11% 6.0%
Accrued Expenses $694.9K $150.6K $174.7K
YoY Change -32.26% -13.79% 53.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.014M $716.6K $698.2K
YoY Change -26.15% 2.63% 14.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.014M $716.6K $698.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.014M $716.6K $698.2K
YoY Change -26.15% 2.63% 14.89%
SHAREHOLDERS EQUITY
Retained Earnings -$62.40M -$59.70M -$48.08M
YoY Change 20.23% 24.16%
Common Stock $25.93K $25.63K $25.63K
YoY Change 1.17% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.487M $8.331M $19.12M
YoY Change
Total Liabilities & Shareholders Equity $7.501M $9.048M $19.82M
YoY Change -55.59% -54.34% -3.34%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$2.717M -$2.500M -$2.612M
YoY Change -28.99% -4.28% 68.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.814M -$2.727M -$2.034M
YoY Change -30.49% 34.07% 161.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -62.35K $6.699M
YoY Change -74.95%
NET CHANGE
Cash From Operating Activities -1.814M -$2.727M -$2.034M
Cash From Investing Activities
Cash From Financing Activities -62.35K $6.699M
Net Change In Cash -1.876M -$2.727M $4.665M
YoY Change -34.37% -158.45% -699.72%
FREE CASH FLOW
Cash From Operating Activities -$1.814M -$2.727M -$2.034M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001815974
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
usd
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 ANEB Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
usd
CY2023Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
CY2023Q3 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
001-40388
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1017 Ranch Road 620 South
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 107
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
CY2023Q3 dei City Area Code
CityAreaCode
(512)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
598-0931
CY2023Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q3 dei Trading Symbol
TradingSymbol
ANEB
CY2023Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25633217 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8520578 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11247403 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
527306 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
422748 usd
CY2023Q3 us-gaap Assets
Assets
9047884 usd
CY2023Q2 us-gaap Assets
Assets
11670151 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
565949 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
534545 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150611 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
534256 usd
CY2023Q3 us-gaap Liabilities
Liabilities
716560 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1068801 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25633217 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25633217 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25633217 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25633217 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
25634 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
25634 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67988554 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67777757 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59682864 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57202041 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8331324 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9047884 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11670151 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1270220 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1223776 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1273458 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1388271 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2543678 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2612047 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2543678 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2612047 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
55198 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7657 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-212 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62855 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-212 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25633217 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25633217 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23416495 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23416495 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15066900 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6397821 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
52400 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
211900 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19117186 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
210797 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8331324 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2611835 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
210797 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
211900 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
104558 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-429292 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31404 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106282 usd
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-383645 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
43003 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2726825 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2033922 usd
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6646748 usd
CY2022Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52400 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6699148 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2726825 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4665226 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11247403 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14548471 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8520578 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19213697 usd
CY2022Q3 ANEB Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
248927 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2500000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59700000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
274225 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
391750 usd
CY2023Q3 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
220168 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
32913 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30998 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
527306 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
422748 usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
116200 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
190121 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
34411 usd
CY2023Q2 ANEB Accrued Research And Development
AccruedResearchAndDevelopment
344135 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150611 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
534256 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0462 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0287 pure
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.60 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.50 pure
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2049313 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.54
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.27
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4420 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2054893 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.53
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
565862 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
882224 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.30
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y1M6D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
361079 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4319543 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4160351 shares

Files In Submission

Name View Source Status
0001493152-23-041171-index-headers.html Edgar Link pending
0001493152-23-041171-index.html Edgar Link pending
0001493152-23-041171.txt Edgar Link pending
0001493152-23-041171-xbrl.zip Edgar Link pending
aneb-20230930.xsd Edgar Link pending
ex10-3.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
aneb-20230930_cal.xml Edgar Link unprocessable
aneb-20230930_def.xml Edgar Link unprocessable
aneb-20230930_lab.xml Edgar Link unprocessable
aneb-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending